Sarcoma-180 (S-180) tumor cells grown in Swiss mice displayed natural resistance to Bouvardin (NSC 259968) when administered alone in a single dose or in multiple doses. Hyperthermia treatment (43 °C for 1 hr) alone did not show any tumor growth reduction. However, the drug combined with hyperthermia markedly reduced tumor growth suggesting that hyperthermia alters the natural resistance of S-180 cells to Bouvardin.
Get full access to this article
View all access options for this article.
References
1.
ChitnisM.P., MateA.D., MenonR.S.: Effect of Bouvardin (NSC 259968) on the growth characteristics and nucleic acids and protein syntheses profiles of P388 leukemia cells.Chemotherapy, 27: 126–130, 1981.
2.
ChitnisM.P., JohnsonR.K.: Biochemical parameters of resistance of an adriamycin-resistant subline of P388 leukemia to emetine, an inhibitor of protein synthesis.J. Natl. Cancer Inst., 60: 1049–1054, 1978.
3.
ChitnisM.P., JoshiS.S., GudeR.P., MenonR.S.: Induced resistance in leukemia L1210 and its cross resistance to vincristine and bouvardin.Chemotherapy, 82: 209–212, 1982.
4.
DicksonJ.A., SuzangarM.: In vitro-in vivo studies on the susceptibility of solid Yoshida sarcoma to drugs and hyperthermia (42 °C).Cancer Res., 34: 1263–1273, 1974.
5.
DicksonJ.A.: The effects of hyperthermia in animal tumour systems.Selective Heat Sensitivity of Cancer Cells.Springer-Verlag, Berlin, Heidelberg, New York, 1977.
6.
HendersonJ.F., BrokemanR.W.: Biochemical mechanisms of drug resistance in cancer chemotherapy.Pharmacological Basis of Cancer Chemotherapy.William and Wilkins Co., Baltimore, 1975.
7.
HermanT.S., CressA.E., GernerE.W.: The use of hyperthermia to overcome methotrexate resistance. Sixty-ninth Annual Meeting of the American Association for Cancer Research, April 5–8, 1978, page 66, Washington, D.C.
8.
InabaM., KoboyashiH., SakuraiY., JohnsonR.K.: Active efflux of daunomycin and adriamycin in sensitive and resistant sublines of P388 leukemia.Cancer Res., 39: 2200–2203, 1979.
9.
JohnsonR.K., ChitnisM.P., GoldinA.: Characteristics of resistance and cross resistance in vivo of a subline of P388 leukemia resistant to adriamycin.Pharmacologist, 18: 173, 1976.
10.
JohnsonR.K., OvejeraA.A., GoldinA.: Activity of anthracyclines against an adriamycin (NSC-123127) resistant subline of P388 leukemia with special emphasis on cinerubin A (NSC 18334).Cancer Treat. Rep., 60: 99–102, 1976.
11.
KleinM.E., FrayerK.: Alterations in secondary adriamycin resistance by amphotericin and hyperthermia: Sixty-ninth Annuel Meeting of the American Association for Cancer Research, April 5–8, 1978, page 84, Washington, D.C.
12.
MondoviE., StormR., RotilioG., Finazzi-AgroA., CavaliereR., Rossi-FanelliA.: The biochemical mechanism of selective sensitivity of cancer cells.I. Studies on cellular respiration. Eur. J. Cancer, 5: 129–136, 1969.
13.
MondoviB., Finazzi-AgroA., RotilioG., StormR., MoriccaG., Rossi-FanelliA.: The biochemical mechanism of selective heat sensitivity of cancer cells.II. Studies on nucleic acids and protein synthesis. Eur. J. Cancer, 5: 137–146, 1969.
14.
MuckleD.S., DicksonJ.A.: Hyperthermia (42 °C) as an adjuvant to radiotherapy and chemotherapy in the treatment of the allogenic VX2 carcinoma in the rabbit.Br. J. Cancer, 27: 307–315, 1973.
15.
Protocols for screening chemical agents and natural products against animal tumours and other biological system CCNSC.Cancer Chemother. Rep., 25: 1, 1962.
16.
StormR., Scioscia-SantoraA., CriffoC., BozziA., MondoviB., Rossi-FanelliA.: The biochemical mechanism of selective heat sensitivity of cancer cells.IV. Inhibition of RNA synthesis. Eur. J. Cancer, 9: 103–112, 1973.
17.
StormR., CaiafaP., MondoviB., Rossi-FanelliA.: Temperature dependence of transcellular migration of glutamate in normal and neoplastic cells.Permeability and function of biological membranes.North Holland Publishing Co., Amsterdam, 1970.
18.
SuzukiK.: Application of heat to cancer chemotherapy.Nagoya J. Med. Sci., 30: 1–21, 1967.
19.
TsuruoT.: Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of VCR and VLB verapmil.Cancer Res., 41: 1967–1972, 1981.
